Effective Combination of CPX-351 with FLT3 Inhibitors in AML Blasts Harboring the FLT3-ITD Mutation

被引：3
|
作者：
Edwards, David K. [1 ]
Javidi-Sharifi, Nathalie [1 ]
Rofelty, Angela [2 ]
Rosenfeld, Claire [3 ]
Roth-Carter, Riley [3 ]
Tardi, Paul [4 ]
Mayer, Lawrence [4 ]
Tyner, Jeffrey W. [1 ]
机构：
[1] Oregon Hlth & Sci Univ, Knight Canc Inst, Dept Cell Dev & Canc Biol, Portland, OR USA
[2] Oregon Hlth & Sci Univ, Knight Canc Inst, Div Hematol & Med Oncol, Portland, OR USA
[3] Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR USA
[4] Jazz Pharmaceut, Vancouver, BC, Canada
来源：
BLOOD | 2016年 / 128卷 / 22期
关键词：
D O I：
10.1182/blood.V128.22.5124.5124
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
5124
引用
收藏
页数：4
相关论文
共 50 条
  • [31] FLT3 Inhibitors in AML
    Stone, R. M.
    ANNALS OF HEMATOLOGY, 2015, 94 (SUPPL 1) : 101 - 102
  • [32] FLT3 Inhibitors in AML
    Perl, Alexander
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2018, 18 : S1 - S2
  • [33] FLT3 Inhibitors in AML
    Stone, R. M.
    ANNALS OF HEMATOLOGY, 2015, 94 : S101 - S102
  • [34] Molecular Analysis and In Vivo Efficacy Studies on a Novel Chemical-Series of FLT3 Inhibitors in Human FLT3-ITD AML
    Melgar, Katelyn
    Walker, MacKenzie
    Jiang, Jiang-kang
    Wison, Kelli
    Choi, Kwangmin
    Mulloy, James C.
    Thomas, Craig J.
    Starczynowski, Daniel T.
    BLOOD, 2016, 128 (22)
  • [35] Erlotinib is effective against FLT3-ITD mutant AML and helps to overcome intratumoral heterogeneity via targeting FLT3 and Lyn
    Cao, Zhi-Xing
    Guo, Chuan-Jie
    Song, Xiaominting
    He, Jun-Lin
    Tan, Lu
    Yu, Si
    Zhang, Ruo-Qi
    Peng, Fu
    Peng, Cheng
    Li, Yu-Zhi
    FASEB JOURNAL, 2020, 34 (08): : 10182 - 10190
  • [36] FLT3 ITD Signaling Profiles in AML Samples Harboring Mutations.
    Minden, M. D.
    Kornblau, Steven M.
    Rosen, David B.
    Cohen, Aileen Cleary
    Gayko, Urte
    Putta, Santosh
    Woronicz, John
    Fantl, Wendy J.
    Cesano, Alessandra
    BLOOD, 2009, 114 (22) : 635 - 635
  • [37] RNA-based FLT3-ITD allelic ratio is associated with outcome and ex vivo response to FLT3 inhibitors in pediatric AML
    Cucchi, David G. J.
    Denys, Barbara
    Kaspers, Gertjan J. L.
    Janssen, Jeroen J. W. M.
    Ossenkoppele, Gert J.
    de Haas, Valerie
    Zwaan, C. Michel
    van den Heuvel-Eibrink, Marry M.
    Philippe, Jan
    Csikos, Tamas
    Kwidama, Zinia
    de Moerloose, Barbara
    de Bont, Eveline S. J. M.
    Lissenberg-Witte, Birgit I.
    Zweegman, Sonja
    Verwer, Femke
    Vandepoele, Karl
    Schuurhuis, Gerrit Jan
    Sonneveld, Edwin
    Cloos, Jacqueline
    BLOOD, 2018, 131 (22) : 2485 - 2489
  • [38] The FLT3 and Pim kinases inhibitor SGI-1776 preferentially target FLT3-ITD AML cells
    Hospital, Marie-Anne
    Green, Alexa S.
    Lacombe, Catherine
    Mayeux, Patrick
    Bouscary, Didier
    Tamburini, Jerome
    BLOOD, 2012, 119 (07) : 1791 - 1792
  • [39] Current Approaches to Transplantation for FLT3-ITD AML
    Bradley D. Hunter
    Yi-Bin Chen
    Current Hematologic Malignancy Reports, 2020, 15 : 1 - 8
  • [40] Current Approaches to Transplantation for FLT3-ITD AML
    Hunter, Bradley D.
    Chen, Yi-Bin
    CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 2020, 15 (01) : 1 - 8
12345